Drug Trial Radar · NCT07609940
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Jul 15, 2026
Primary completion
Oct 11, 2027
Study completion Dec 6, 2028
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- May 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching whether the use of tocilizumab before the first dose of linvoseltamab will decrease the risk of Cytokine Release Syndrome (CRS) in participants who have Relapsed or Refractory Multiple Myeloma (RRMM) who have already been treated with at least four lines of treatment for their multiple myeloma, including medicines called a proteasome inhibitor, an immunomodulatory drug, and an anti-Cluster of Differentiation (CD) 38 antibody. The aim of the study is to see how safe, tolerable and effective linvoseltamab is when given after tocilizumab. The study is looking at several other research questions, including: * What side effects may happen from taking tocilizumab before the first dose of linvoseltamab * Whether tocilizumab has an impact on CRS, including whether participants require hospital care and, if so, how many hospital visits occur and how long they last * How frequently other medications (for example, corticosteroids or additional doses of tocilizumab) are used to support participants' care if needed
Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
Interventions
LinvoseltamabDrug
Administered per the protocol
TocilizumabDrug
Administered per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of any grade CRS per American Society for Transplantation and Cellular Therapy (ASTCT) gradingTime frame: Up to 28 days
- Severity of any grade CRS per ASTCT gradingTime frame: Up to 28 days
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Berenson Cancer Center
Los Angeles, California · Recruiting
Comprehensive Hematology Oncology
St. Petersburg, Florida · Recruiting
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana · Recruiting
American Oncology Partners, PA dba The Center for Cancer and Blood Disorders
Bethesda, Maryland · Recruiting
Renown Health Medical Oncology
Reno, Nevada · Recruiting
Texas Tech University Health Science Center School of Medicine
Lubbock, Texas · Recruiting
Northwest Medical Specialties, PLLC
Tacoma, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.